KR102657978B1 - 특이적 결합 분자 - Google Patents

특이적 결합 분자 Download PDF

Info

Publication number
KR102657978B1
KR102657978B1 KR1020207009544A KR20207009544A KR102657978B1 KR 102657978 B1 KR102657978 B1 KR 102657978B1 KR 1020207009544 A KR1020207009544 A KR 1020207009544A KR 20207009544 A KR20207009544 A KR 20207009544A KR 102657978 B1 KR102657978 B1 KR 102657978B1
Authority
KR
South Korea
Prior art keywords
ser
gly
thr
ala
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207009544A
Other languages
English (en)
Korean (ko)
Other versions
KR20200062215A (ko
Inventor
오비나 우바
캐롤린 바렐
앤드류 포터
Original Assignee
엘라스모겐 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엘라스모겐 리미티드 filed Critical 엘라스모겐 리미티드
Publication of KR20200062215A publication Critical patent/KR20200062215A/ko
Application granted granted Critical
Publication of KR102657978B1 publication Critical patent/KR102657978B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020207009544A 2017-09-27 2018-09-27 특이적 결합 분자 Active KR102657978B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762563948P 2017-09-27 2017-09-27
US62/563,948 2017-09-27
US201862667126P 2018-05-04 2018-05-04
US62/667,126 2018-05-04
PCT/EP2018/076333 WO2019063726A1 (en) 2017-09-27 2018-09-27 SPECIFIC BINDING MOLECULES

Publications (2)

Publication Number Publication Date
KR20200062215A KR20200062215A (ko) 2020-06-03
KR102657978B1 true KR102657978B1 (ko) 2024-04-16

Family

ID=63720686

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207009544A Active KR102657978B1 (ko) 2017-09-27 2018-09-27 특이적 결합 분자

Country Status (7)

Country Link
US (2) US11919949B2 (https=)
EP (2) EP3688030B1 (https=)
JP (3) JP2020535811A (https=)
KR (1) KR102657978B1 (https=)
CN (1) CN111479825A (https=)
CA (1) CA3075367A1 (https=)
WO (1) WO2019063726A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190233832A1 (en) * 2016-07-19 2019-08-01 National Agriculture And Food Research Organization Method for introducing substance into plant cell using plasma
WO2021028837A1 (en) * 2019-08-13 2021-02-18 Waters Technologies Corporation Affinity resins and sample preparation devices based on cartilaginous fish ignar derived binding domains
GB202020152D0 (en) * 2020-12-18 2021-02-03 Elasmogen Ltd Fast-track humanisation of specific binding molecules
CN118475603A (zh) * 2021-11-03 2024-08-09 香港城市大学深圳研究院 高亲和力抗EGFP和抗SARS-CoV-2 vNAR单域抗体及其用途
GB202407865D0 (en) 2024-06-03 2024-07-17 Elasmogen Ltd Self immolative compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015200883A2 (en) * 2014-06-26 2015-12-30 Ossianix, Inc. Semi-synthetic nurse shark vnar libraries for making and using selective binding compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
PT1419179E (pt) 2001-08-10 2010-03-16 Univ Aberdeen Domínios de ligação de antigenes
JP2008511286A (ja) 2004-06-02 2008-04-17 ダイアテック・ピーティワイ・リミテッド サメ類のＩｇＮＡＲドメインに基づく結合成分
WO2011056056A2 (es) 2009-11-04 2011-05-12 Laboratorios Silanes, S.A. De C.V. Dominios vhnar anti -citocinas
PE20141522A1 (es) * 2011-08-17 2014-11-17 Glaxo Group Ltd Proteinas y peptidos modificados
EP4151658A1 (en) 2012-05-07 2023-03-22 Elasmogen Limited Single domain binding molecule
JP6616284B2 (ja) 2013-04-23 2019-12-04 ザ ユニバーシティ コート オブ ザ ユニバーシティ オブ アバディーン 特異的結合分子の人工ライブラリー

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015200883A2 (en) * 2014-06-26 2015-12-30 Ossianix, Inc. Semi-synthetic nurse shark vnar libraries for making and using selective binding compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
D. Könning et al. Scientific Reports. 2017.8.29.공개, Vol.7. Article number:9676*
M. Kovaleva et al. Expert Opinion on Biological Therapy. 2014, Vol.14, pp.1527-1539*

Also Published As

Publication number Publication date
JP2025160405A (ja) 2025-10-22
JP7818828B2 (ja) 2026-02-24
US20240247058A1 (en) 2024-07-25
JP2023175822A (ja) 2023-12-12
US11919949B2 (en) 2024-03-05
EP3688030A1 (en) 2020-08-05
CN111479825A (zh) 2020-07-31
KR20200062215A (ko) 2020-06-03
WO2019063726A1 (en) 2019-04-04
CA3075367A1 (en) 2019-04-04
EP4570826A3 (en) 2025-09-24
US12371484B2 (en) 2025-07-29
US20200407437A1 (en) 2020-12-31
JP2020535811A (ja) 2020-12-10
EP4570826A2 (en) 2025-06-18
EP3688030B1 (en) 2024-12-11

Similar Documents

Publication Publication Date Title
KR102657978B1 (ko) 특이적 결합 분자
KR102364599B1 (ko) Cd40 및 fap에 특이적으로 결합할 수 있는 새로운 이중특이적 항원 결합 분자
CN110719920B (zh) 蛋白质异二聚体及其用途
CN107001485B (zh) 蛋白质异二聚体及其用途
US9212231B2 (en) TRAIL R2-specific multimeric scaffolds
KR101900953B1 (ko) Ｃｄ86 길항제 다중-표적 결합 단백질
CN106715470B (zh) 与pd-1和lag-3具有免疫反应性的共价结合的双抗体和其使用方法
KR102466763B1 (ko) 항- psma 항체 및 이의 용도
TWI688572B (zh) 包含dr5-結合結構域的多價分子
KR102649757B1 (ko) 5t4 및 4-1bb에 결합하는 항원 결합 단백질 및 관련 조성물 및 방법
KR20150139531A (ko) 이중특이적 이가 scFv-Ｆｃ 분자
KR20190004802A (ko) Tnf 계열 리간드 삼량체 및 pd1 결합 잔기를 포함하는 항원 결합 분자
TR201808591T4 (tr) Bir evrensel bir antikor iskeleti kullanılarak tavşan antikorların insanlaştırılması.
KR20150041626A (ko) 아시알로당단백질 수용체 항체 및 이의 용도
KR20180053674A (ko) 공자극 tnf 수용체에 특이적인 이중특이성 항체
KR20170085552A (ko) Tnf 계열 리간드 삼량체를 포함하는 항원 결합 분자
KR20170081188A (ko) Folr1 및 cd3에 대한 t 세포 활성화 이중특이적 항원 결합 분자
KR20230163485A (ko) 면역 이펙터 세포 재유도를 위한 물질 및 방법
US20250346659A1 (en) Specific binding molecules
RU2804458C2 (ru) Антигенсвязывающие белки, связывающиеся с 5t4 и 4-1bb, и относящиеся к ним композиции и способы

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200401

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210924

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230828

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240206

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240411

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240412

End annual number: 3

Start annual number: 1

PG1601 Publication of registration